Search Results - "Leung, Cheuk H."

Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy by Weissferdt, Annikka, Leung, Cheuk H, Lin, Heather, Sepesi, Boris, William, William N, Swisher, Stephen G, Cascone, Tina, Lee, J Jack, Pataer, Abujiang

“…Neoadjuvant treatment of non-small cell lung cancer challenges the traditional processing of pathology specimens. Induction therapy before resection allows…”
Get full text

Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer by Sepesi, Boris, Zhou, Nicolas, William, William N., Lin, Heather Y., Leung, Cheuk H., Weissferdt, Annikka, Mitchell, Kyle G., Pataer, Apar, Walsh, Garrett L., Rice, David C., Roth, Jack A., Mehran, Reza J., Hofstetter, Wayne L., Antonoff, Mara B., Rajaram, Ravi, Negrao, Marcelo V., Tsao, Anne S., Gibbons, Don L., Lee, J. Jack, Heymach, John V., Vaporciyan, Ara A., Swisher, Stephen G., Cascone, Tina

“…Surgical outcomes for non–small cell lung cancer after neoadjuvant immune checkpoint inhibitors continue to be debated. We assessed perioperative outcomes of…”
Get full text

Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis by Molina, Sofia, Martinez-Zayas, Gabriela, Sainz, Paula V, Leung, Cheuk H, Li, Liang, Grosu, Horiana B, Adachi, Roberto, Ost, David E

“…Evidence-based guidelines recommend management strategies for malignant pleural effusions (MPEs) based on life expectancy. Existent risk-prediction rules do…”
Get full text

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer by Cascone, Tina, Weissferdt, Annikka, Godoy, Myrna C. B., William, William N., Leung, Cheuk H., Lin, Heather Y., Basu, Sreyashi, Yadav, Shalini S., Pataer, Apar, Mitchell, Kyle G., Khan, Md Abdul Wadud, Shi, Yushu, Haymaker, Cara, Solis, Luisa M., Parra, Edwin R., Kadara, Humam, Wistuba, Ignacio I., Sharma, Padmanee, Allison, James P., Ajami, Nadim J., Wargo, Jennifer A., Jenq, Robert R., Gibbons, Don L., Lee, J. Jack, Swisher, Stephen G., Vaporciyan, Ara A., Heymach, John V., Sepesi, Boris

“…Radiographic imaging is the standard approach for evaluating the disease involvement of lymph nodes in patients with operable NSCLC although the impact of…”
Get full text

Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer by Feldman, Hope, Sepesi, Boris, Leung, Cheuk H., Lin, Heather, Weissferdt, Annikka, Pataer, Apar, William, William N., Walsh, Garrett L., Rice, David C., Roth, Jack A., Mehran, Reza J., Hofstetter, Wayne L., Antonoff, Mara B., Rajaram, Ravi, Gibbons, Don L., Lee, J. Jack, Heymach, John V., Vaporciyan, Ara A., Swisher, Stephen G., Cascone, Tina

“…Chemotherapy plus nivolumab is the standard of care neoadjuvant treatment for patients with resectable stage IB to IIIA non–small cell lung cancer. The…”
Get full text

Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas by Panse, Gauri, Chrisinger, John SA, Leung, Cheuk H, Ingram, Davis R, Khan, Samia, Wani, Khalida, Lin, Heather, Lazar, Alexander J, Wang, Wei‐Lien

“…Aims Multiple genetic alterations, including alternative lengthening of telomeres (ALT) and NOTCH mutations, have been described in angiosarcoma. Loss of…”
Get full text

Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer by Altan, Mehmet, Singhi, Eric K., Worst, Michelle, Carter, Brett W., Leung, Cheuk H., Lee, J. Jack, Presley, Carolyn J., Lewis, Jeff, Rinsurongkawong, Waree, Rinsurongkawong, Vadeerat, Zhang, Jianjun, Gibbons, Don L., Vaporciyan, Ara A., Heymach, John V., Mott, Frank E.

“…As a result of the approval of several immune checkpoint inhibitors (ICIs) for the treatment of non-small cell lung cancer (NSCLC), many older adults are being…”
Get full text

The immune landscape of undifferentiated pleomorphic sarcoma by Lazcano, Rossana, Barreto, Carmelia M., Salazar, Ruth, Carapeto, Fernando, Traweek, Raymond S., Leung, Cheuk H., Gite, Swati, Mehta, Jay, Ingram, Davis R., Wani, Khalida M., Vu, Kim-Anh T., Parra, Edwin R., Lu, Wei, Zhou, Jianling, Witt, Russell G., Cope, Brandon, Thirasastr, Prapassorn, Lin, Heather Y., Scally, Christopher P., Conley, Anthony P., Ratan, Ravin, Livingston, J. Andrew, Zarzour, Alexandra M., Ludwig, Joseph, Araujo, Dejka, Ravi, Vinod, Patel, Shreyaskumar, Benjamin, Robert, Wargo, Jennifer, Wistuba, Ignacio I., Somaiah, Neeta, Roland, Christina L., Keung, Emily Z., Solis, Luisa, Wang, Wei-Lien, Lazar, Alexander J., Nassif, Elise F.

“…Introduction Undifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1,…”
Get full text

The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumours by Panse, Gauri, Leung, Cheuk H, Ingram, Davis R, Wani, Khalida, Torres, Keila E, Lin, Heather, Lazar, Alexander J, Wang, Wei‐Lien

“…Aims STAT3 is a pro‐oncogenic transcription factor that requires phosphorylation for transcriptional activation. The aim of this study was to evaluate the role…”
Get full text

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer by Zhou, Nicolas, Leung, Cheuk H, William, Jr, William N, Weissferdt, Annikka, Pataer, Apar, Godoy, Myrna C B, Carter, Brett W, Fossella, Frank V, Tsao, Anne S, Blumenschein, George R, Le, Xiuning, Zhang, Jianjun, Skoulidis, Ferdinandos, Kurie, Jonathan M, Altan, Mehmet, Lu, Charles, Glisson, Bonnie S, Byers, Lauren A, Elamin, Yasir Y, Mehran, Reza J, Rice, David C, Walsh, Garrett L, Hofstetter, Wayne L, Roth, Jack A, Tran, Hai T, Wu, Jia, Solis Soto, Luisa M, Kadara, Humam, Swisher, Stephen G, Vaporciyan, Ara A, Gibbons, Don L, Lin, Heather Y, Lee, J Jack, Heymach, John V, Negrao, Marcelo V, Sepesi, Boris, Cascone, Tina

“…Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC)…”
Get full text

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial by Cascone, Tina, William, William N., Weissferdt, Annikka, Leung, Cheuk H., Lin, Heather Y., Pataer, Apar, Godoy, Myrna C. B., Carter, Brett W., Federico, Lorenzo, Reuben, Alexandre, Khan, Md Abdul Wadud, Dejima, Hitoshi, Francisco-Cruz, Alejandro, Parra, Edwin R., Solis, Luisa M., Fujimoto, Junya, Tran, Hai T., Kalhor, Neda, Fossella, Frank V., Mott, Frank E., Tsao, Anne S., Blumenschein, George, Le, Xiuning, Zhang, Jianjun, Skoulidis, Ferdinandos, Kurie, Jonathan M., Altan, Mehmet, Lu, Charles, Glisson, Bonnie S., Byers, Lauren Averett, Elamin, Yasir Y., Mehran, Reza J., Rice, David C., Walsh, Garrett L., Hofstetter, Wayne L., Roth, Jack A., Antonoff, Mara B., Kadara, Humam, Haymaker, Cara, Bernatchez, Chantale, Ajami, Nadim J., Jenq, Robert R., Sharma, Padmanee, Allison, James P., Futreal, Andrew, Wargo, Jennifer A., Wistuba, Ignacio I., Swisher, Stephen G., Lee, J. Jack, Gibbons, Don L., Vaporciyan, Ara A., Heymach, John V., Sepesi, Boris

“…Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune…”
Get full text

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial by Cascone, Tina, Leung, Cheuk H., Weissferdt, Annikka, Pataer, Apar, Carter, Brett W., Godoy, Myrna C. B., Feldman, Hope, William, William N., Xi, Yuanxin, Basu, Sreyashi, Sun, Jing Jing, Yadav, Shalini S., Rojas Alvarez, Frank R., Lee, Younghee, Mishra, Aditya K., Chen, Lili, Pradhan, Monika, Guo, Haiping, Sinjab, Ansam, Zhou, Nicolas, Negrao, Marcelo V., Le, Xiuning, Gay, Carl M., Tsao, Anne S., Byers, Lauren Averett, Altan, Mehmet, Glisson, Bonnie S., Fossella, Frank V., Elamin, Yasir Y., Blumenschein, George, Zhang, Jianjun, Skoulidis, Ferdinandos, Wu, Jia, Mehran, Reza J., Rice, David C., Walsh, Garrett L., Hofstetter, Wayne L., Rajaram, Ravi, Antonoff, Mara B., Fujimoto, Junya, Solis, Luisa M., Parra, Edwin R., Haymaker, Cara, Wistuba, Ignacio I., Swisher, Stephen G., Vaporciyan, Ara A., Lin, Heather Y., Wang, Jing, Gibbons, Don L., Jack Lee, J., Ajami, Nadim J., Wargo, Jennifer A., Allison, James P., Sharma, Padmanee, Kadara, Humam, Heymach, John V., Sepesi, Boris

“…Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with…”
Get full text

Breast and Lung Effusion Survival Score Models by Molina, Sofia, Martinez-Zayas, Gabriela, Sainz, Paula V., Leung, Cheuk H., Li, Liang, Grosu, Horiana B., Adachi, Roberto, Ost, David E.

“…Evidence-based guidelines recommend management strategies for malignant pleural effusions (MPEs) based on life expectancy. Existent risk-prediction rules do…”
Get full text

Abstract 3857: Characterization of immune cell biomarkers in undifferentiated pleomorphic sarcoma by Barreto, Carmelia M., Solis-Soto, Luisa M., Salazar, Ruth, Gite, Swati, Parra, Edwin R., Mino, Barbara, Ingram, Davis, Wani, Khalida M., Leung, Cheuk H., Lin, Heather, Wistuba, Ignacio I., Lazar, Alexander, Wang, Wei-Lien

“…Abstract Background: Undifferentiated pleomorphic sarcoma (UPS) are genetically complex sarcomas often showing a relatively higher immune infiltration among…”
Get full text